Alexion Gets Speedy Review For Soliris Successor
Switching patients from the very expensive ultra rare disorder drug to ravulizumab will be a key strategy for Alexion if the latter is approved. Recent compelling data in paroxysmal nocturnal hemoglobinuria patients suggests the long-acting C5 complement inhibitor could offer more benefit than its predecessor with more convenient dosing.
You may also be interested in...
Alexion’s third deal this year brings privately held Syntimmune and its Phase Ib/IIa candidate for three IgG-mediated rare disorders, including warm autoimmune hemolytic anemia, for a $400m upfront price tag.
Sanofi executive offers five-year voucher life-span as potential option for sustaining the resale market.
Alexion Pharmaceuticals’ successor to its blockbuster Soliris is among the new investigational drugs being reviewed for EU marketing approval.